NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

Phase 2

Completed

Conditions: HIV Infections
Toxoplasmosis, Cerebral

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT00000794

Locations: 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

and more 13 locations

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

Phase 1

Completed

Conditions: HIV Infections
HIV Seronegativity

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT00000868

Locations: 🇺🇸
JHU AVEG, Baltimore, Maryland, United States

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00000767

Locations: 🇺🇸
JHU AVEG, Pittsburgh, Pennsylvania, United States
🇺🇸
Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States

and more 2 locations

Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients

Phase 1

Terminated

Conditions: Kidney Transplant Recipients

Interventions: Biological: Varivax®

First Posted Date: 2001-08-31

Last Posted Date: 2017-02-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 7

Registration Number: NCT00005009

Locations: 🇺🇸
University of Michigan - Vaccine and Treatment Evaluation Unit (VTEU), Ann Arbor, Michigan, United States
🇺🇸
Boston Children's Hospital - Vaccine and Treatment Evaluation Unit (VTEU), Boston, Massachusetts, United States
🇺🇸
University of Alabama at Birmingham - Vaccine and Treatment Evaluation Unit (VTEU), Birmingham, Alabama, United States

and more 1 locations

Treatment of Chronic Cryptosporidiosis in AIDS Patients

Not Applicable

Terminated

Conditions: Cryptosporidiosis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2016-12-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT00001128

Locations: 🇺🇸
Pablo C. Okhuysen, Houston, Texas, United States

A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3

Not Applicable

Terminated

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2016-12-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00001064

Locations: 🇺🇸
Stanford Univ School of Medicine, Stanford, California, United States

Phase I Trial of an Intervention to Increase Condom Use by HIV-Discordant Couples

Phase 1

Completed

Conditions: HIV Infections

Interventions: Behavioral: Group counseling intervention

First Posted Date: 2001-08-31

Last Posted Date: 2016-11-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 90

Registration Number: NCT00000928

Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women

Completed

Conditions: HIV Infections
Pregnancy

First Posted Date: 2001-08-31

Last Posted Date: 2006-08-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 160

Registration Number: NCT00017797

Locations: 🇺🇸
The CORE Ctr, Chicago, Illinois, United States
🇺🇸
Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Univ of Miami (Pediatric), Miami, Florida, United States

and more 37 locations

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

Phase 1

Completed

Conditions: HIV Infections
HIV Seronegativity
Lipodystrophy

First Posted Date: 2001-08-31

Last Posted Date: 2006-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 56

Registration Number: NCT00017758

Locations: 🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸
Univ of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Washington Univ School of Medicine, St Louis, Missouri, United States

and more 7 locations

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00000663

Locations: 🇺🇸
Texas Children's Hosp / Baylor Univ, Houston, Texas, United States
🇺🇸
Cook County Hosp, Chicago, Illinois, United States
🇺🇸
UCSD Treatment Ctr, San Diego, California, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy